Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

This study has been completed.
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC Identifier:
First received: December 3, 2010
Last updated: April 21, 2014
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 26, 2014